Latest 3 stories · newest Aug 3, 2026
TG Therapeutics reported Q2 2026 total global revenue of approximately $240 million, exceeding its guidance. The company raised its full year financial targets as BRIUMVI commercial performance continues to outperform expectations.
TG Therapeutics announced positive pharmacokinetic and pharmacodynamic results from a Phase 1 trial of subcutaneous BRIUMVI, demonstrating greater than 60% bioavailability and supporting quarterly dosing. Phase 3 data is expected by end of 2026 or early 2027, with potential approval in 2028 for what…
TG Therapeutics announced positive Phase 3 results showing bioequivalent drug exposure between a new single 600mg Day 1 infusion versus the current two-infusion regimen for BRIUMVI in multiple sclerosis patients. The company plans to file a supplemental BLA in 2H-2026, potentially positioning BRIUMV…
The same TGTX feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/TGTX/newsSTART FREE